NCT06799286View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

May 26, 2027

Study Completion Date

May 26, 2027

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

BMS-986489

Specified dose on specified days

Trial Locations (5)

100142

Local Institution - 0004, Beijing

200120

Local Institution - 0002, Shanghai

250117

Local Institution - 0003, Jinan

276001

Local Institution - 0001, Linyi

310016

Local Institution - 0005, Hangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY